Biotech Values

[biomaven0]

However, the 0.92 figure is not final, so it could improve when all of the survival data are in.

I'm guessing it will. If you assume there is a subset that responds to the drug and has a pronounced survival advantage, then immature data will likely look worse than mature data.

Not surprised at the weakness today - lot of momo players in the stock ready to be shaken out. I hate being invested in stocks with momo players at all, but alas I can't choose my fellow investors. (Suppose I could go to the ARIA thread and make a "the world is coming to an end" post to try to improve the average quality though - but maybe the response would be that I got the date wrong and it's
actually only happening on May 21st). :)


Peter